457 related articles for article (PubMed ID: 29978755)
1. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
Cheng HG; Coplan PM
Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
[TBL] [Abstract][Full Text] [Related]
2. Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013.
Jones CM; Muhuri PK; Lurie PG
Clin J Pain; 2017 May; 33(5):452-461. PubMed ID: 27513641
[TBL] [Abstract][Full Text] [Related]
3. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
Hwang CS; Chang HY; Alexander GC
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
[TBL] [Abstract][Full Text] [Related]
5. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
6. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
[TBL] [Abstract][Full Text] [Related]
7. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
[TBL] [Abstract][Full Text] [Related]
8. Discrepancies in prevalence estimates in two national surveys for nonmedical use of a specific opioid product versus any prescription pain reliever.
Biondo G; Chilcoat HD
Drug Alcohol Depend; 2014 Jan; 134():396-400. PubMed ID: 24210422
[TBL] [Abstract][Full Text] [Related]
9. The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation.
Wolff C; Dowd WN; Ali MM; McClellan C; Meinhofer A; Glos L; Mutter R; Rosenberg M; Schick A
Addict Behav; 2020 Jun; 105():106268. PubMed ID: 32036188
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
[TBL] [Abstract][Full Text] [Related]
11. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
[TBL] [Abstract][Full Text] [Related]
12. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC
Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195
[TBL] [Abstract][Full Text] [Related]
13. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
[TBL] [Abstract][Full Text] [Related]
14. Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.
Janoff SL; Perrin NA; Coplan PM; Chilcoat HD; Campbell CI; Green CA
BMC Pharmacol Toxicol; 2016 May; 17(1):21. PubMed ID: 27177423
[TBL] [Abstract][Full Text] [Related]
15. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
[TBL] [Abstract][Full Text] [Related]
16. Adverse health effects of abuse-deterrent opioids: Evidence from the reformulation of OxyContin.
Beheshti D
Health Econ; 2019 Dec; 28(12):1449-1461. PubMed ID: 31715653
[TBL] [Abstract][Full Text] [Related]
17. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
[TBL] [Abstract][Full Text] [Related]
18. Non-medical use of OxyContin Tablets in the United States.
Sees KL; Di Marino ME; Ruediger NK; Sweeney CT; Shiffman S
J Pain Palliat Care Pharmacother; 2005; 19(2):13-23. PubMed ID: 16061457
[TBL] [Abstract][Full Text] [Related]
19. Internet-based survey of nonmedical prescription opioid use in the United States.
Katz N; Fernandez K; Chang A; Benoit C; Butler SF
Clin J Pain; 2008; 24(6):528-35. PubMed ID: 18574362
[TBL] [Abstract][Full Text] [Related]
20. Toward primary prevention of extra-medical OxyContin® use among young people.
Deandrea DC; Troost JP; Anthony JC
Prev Med; 2013 Sep; 57(3):244-6. PubMed ID: 23701847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
